Vulvovaginal candidiasis is a serious health problem affecting numerous women around the world. Its treatment is based on antifungals which may not provide an effective cure because of the resistance presented by its etiological pathogens Candida spp. Candida albicans is the most prevalent species related to vulvovaginal candidiasis. Here, we evaluated the in vivo antifungal potential of thiosemicarbazide and thiosemicarbazide encapsulated within chitosan nanoparticles in a murine model of vulvovaginal candidiasis. The results demonstrated the antifungal capacity of free or nanoencapsulated thiosemicarbazide within chitosan to reduce the fungal load in the vaginal tissue of infected mice. In addition, histological analyses indicated the absence or a mild to moderate infection in thiosemicarbazide-treated groups. Statistical tests confirmed the existence of significant differences between the treated and the control groups. Therefore, our results suggest a potential application of thiosemicarbazide and encapsulated thiosemicarbazide as an alternative vulvovaginal candidiasis therapy.

中文翻译：

---

在外阴阴道念珠菌病小鼠模型中研究氨基硫脲游离或壳聚糖纳米颗粒内

外阴阴道念珠菌病是一种严重的健康问题，影响着世界各地的众多女性。它的治疗基于抗真菌剂，由于其病原体念珠菌属存在耐药性，因此可能无法提供有效的治愈。白色念珠菌是与外阴阴道念珠菌病相关的最普遍的物种。在这里，我们在外阴阴道念珠菌病的小鼠模型中评估了氨基硫脲和封装在壳聚糖纳米颗粒中的氨基硫脲的体内抗真菌潜力。结果证明了壳聚糖中游离或纳米囊封的氨基硫脲的抗真菌能力，以减少受感染小鼠阴道组织中的真菌负荷。此外，组织学分析表明氨基硫脲治疗组没有或轻度至中度感染。统计检验证实治疗组和对照组之间存在显着差异。因此，我们的结果表明氨基硫脲和胶囊化氨基硫脲作为外阴阴道念珠菌病的替代疗法的潜在应用。